Perivascular adipose tissue (PVAT) is recognized for its vasoactive effects, but it is unclear how metabolic syndrome impacts thoracic aorta (t)PVAT and the subsequent effect on functional and structural aortic stiffness. Thoracic aorta and tPVAT were removed from 16-to 17-weekold lean (LZR, n = 16) and obese Zucker rats (OZR, n = 16). The OZR presented with aortic endothelial dysfunction, assessed by wire myography, and increased aortic stiffness, assessed by elastic modulus. The OZR tPVAT exudate further exacerbated the endothelial dysfunction, reducing nitric oxide and endothelium-dependent relaxation (P < 0.05). Additionally, OZR tPVAT exudate had increased MMP9 activity (P < 0.05) and further increased the elastic modulus of the aorta after 72 h of co-culture (P < 0.05). We found that the observed aortic dysfunction caused by OZR tPVAT was mediated through increased production and release of tumour necrosis factor-(TNF ; P < 0.01), which was dependent on tPVAT NADPH-oxidase 2 (NOX2) activity.
INTRODUCTION
A clustering of cardiovascular risk factors, known as metabolic syndrome (MetS), is associated with increases in oxidative stress and inflammation leading to vascular dysfunction (Brooks et al., 2015; Donley et al., 2014; Katakam et al., 2006) . In MetS, the aorta becomes less compliant through an increase in both functional and structural stiffness. Functional stiffness arises from reduced nitric oxide (NO) bioavailability increasing smooth muscle tone and redistributing circumferential stress onto the extracellular matrix (ECM; Wilkinson, Franklin, & Cockcroft, 2004) . The remodelling of the ECM, fragmentation of elastin and deposition of collagen, are the hallmark of structural stiffness (Fitch, Vergona, Sullivan, & Wang, 2001; Lakatta & Levy, 2003) . The resulting loss of aortic compliance increases afterload c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society on the heart (O' Rourke, 1990) , reduces coronary perfusion (Lakatta & Levy, 2003) and increases pulsatile flow to the periphery (Levy, Ambrosio, Pries, & Struijker-Boudier, 2001 ), which can ultimately lead to end-organ damage (Saji, Kimura, Shimizu, & Kita, 2012) . Perivascular adipose tissue (PVAT) surrounds much of the vasculature and has various phenotypes and functions depending on location. Over the past decade, PVAT has been shown actively to regulate vascular function. Unlike other PVAT depots, 'brown-like' thoracic (t)PVAT encases the aorta and releases vasoactive factors, which promote beneficial vascular effects through the promotion of NO production (Gao, Lu, Su, Sharma, & Lee, 2007) . In disease states, PVAT becomes dysfunctional and shifts towards a pro-oxidative and pro-inflammatory state (Chen et al., 2013; Mikolajczyk et al., 2016) . Recently, in both human and mouse visceral adipose tissue, proteasome function was linked to tissue dysfunction (Díaz-Ruiz et al., 2015) , which might promote ubiquitin-mediated inflammation (Ghosh et al., 2015) . This potential mechanism of adipose dysfunction and inflammation is currently unexplored in PVAT. Of particular interest is the cytokine tumour necrosis factor-(TNF ), which has a potent vasoactive effect, induces the production of inflammatory cytokines, including its own transcription (Chen, Zhang, Zhao, & Medford, 2004; Parameswaran & Patial, 2010) , and activates the production of reactive oxygen species (ROS) from oxidative enzymes, such as NADPH oxidase (Chen et al., 2004; Kim, Morgan, Choksi, & Liu, 2007) .
Data from peripheral PVAT depots highlight the detrimental impact of a pro-oxidative and pro-inflammatory state on small artery function (Greenstein et al., 2009; Virdis et al., 2015) , especially endotheliumdependent dilatation (EDD). Studies show that pathological ECM remodelling and arterial stiffness are mediated through reductions in NO and EDD (Fitch et al., 2001; Gurjar, Sharma, & Bhalla, 1999; Jenkins et al., 1998) . These previous studies highlight the effects of individual disease states, but the effect of the concurrent risk factors in MetS on tPVAT function is limited. However, much of the current MetS literature on PVAT function is in depots surrounding mesenteric or small resistance arterioles. Significant aortic dysfunction has been shown previously in a rat model of MetS, the obese Zucker rat (Mingorance et al., 2009 ). However, it remains unknown to what extent tPVAT affects the pathological changes in MetS and how it regulates aortic function, which is key to understanding the vascular consequences of MetS and developing effective therapeutics.
Thus, the aim of the present study was to uncover key pathways that drive tPVAT dysfunction and the subsequent mediators of aortic impairment in MetS. We hypothesize that phenotypic shifts in MetS tPVAT lead to an increase in ROS production from TNF activation of NADPH-oxidase 2 (NOX2). We further hypothesize that tPVAT-derived pro-inflammatory cytokines activate ROS production in the aorta, diminishing NO bioavailability, with subsequent aortic dysfunction.
METHODS

Ethical approval
Zucker rats from Envigo (Millstone, NJ, USA) were used to conduct the experiments reported in this manuscript on an approved protocol (no. 163000971) by the West Virginia University Health Science Center Animal Care and Use Committee, which meets the US National Insitutes of Health guidelines for care and use of laboratory animals and complies with the animal use ethics checklist set forth by Experimental Physiology.
Animals
Male lean (LZR) and obese Zucker rats (OZR) were purchased from Envigo Laboratories at 8-9 weeks of age (n = 16 per group). Animals were housed at the West Virginia University Health Science Center animal care facility and received standard chow and tap water ad
New Findings
• What is the central question of this study?
Tumour necrosis factor-(TNF ) has been shown to impair vascular function, but the impact of thoracic aorta perivascular adipose tissue (tPVAT)-derived TNF on tPVAT and aortic function in metabolic syndrome is unknown.
• What is the main finding and its importance?
Release of TNF by tPVAT causes production of reactive oxygen species in tPVAT through activation of an NADPH-oxidase 2 (NOX2)-dependent pathway, activates production of aortic reactive oxygen species and mediates aortic stiffness, potentially through matrix metalloproteinase 9 activity. Neutralization of TNF and/or inhibition of NOX2 blocks the tPVAT-induced impairment of aortic function. These data partly implicate tPVAT NOX2 and TNF in mediating the vascular pathology of metabolic syndrome.
libitum. At the time of terminal procedures, 16-to 17-week-old animals were weighed then deeply anaesthetized by I.P. injection of pentobarbital sodium (50 mg kg −1 , Diamondback Drugs, Scottsdale, AZ, USA), and the trachea was intubated to aid in keeping a patent airway. All rats then received carotid artery and jugular vein cannulation to measure mean arterial pressure and to administer heparin, respectfully. Animals were then killed via severing of the diaphragm and subsequent removal of the aorta, which was placed in ice-cold Krebs-Henseleit buffer (mM: 1.18 KH 2 PO 4 , 1.2 MgSO 4 .7H 2 O, 4.7 KCl, 25 NaHCO 3 , 118 NaCl, 5.5 glucose, 0.026 EDTA and 2.5 CaCl 2 .2H 2 O, bubbled with 95% O 2 and 5% CO 2 ). The tPVAT was then carefully removed from the aorta under a dissecting microscope. The aorta was cut into 3 mm rings, and tPVAT was portioned out to examine gene expression, inflammatory mediators and its role in aortic function.
Gene expression
Portions of tPVAT weighing 50 mg were incubated at 37 • C in physio- at 200 g ml −1 . After 1 h, the tPVAT was removed and snap frozen.
To assess gene expression, tPVAT was homogenized in QIAzol and processed for qPCR using the RNeasy Lipid Tissue MiniKit (Qiagen, Valencia, CA, USA) and QuantiTect reverse transcription kit (Qiagen 205313). Equal concentrations of cDNA were then loaded into the QIAgility (Qiagen), which mixed 20 l PCRs with QuantiTect primer assays [adiponectin (QT01169343), -actin (QT00193473), catalase (QT00182700), Chemokine (C-C motif) ligand 5 (CCL5; QT01083614), C-C chemokine receptor type 3 (CCR3; QT00183925), C-C chemokine receptor type 5 (CCR5; QT01084034), cluster of differentiation 4 (CD4; QT00181811), cluster of differentiation 68 (CD68; QT00372204), cluster of differentiation 8a (CD8a; QT00177261), glutathione-disulfide reductase (GSR; QT01083285), Interferon gamma (IFN-; QT00184982), Interleukin 10 (IL-10; QT00177618), Interleukin 13 (IL-13; QT00184842), Interleukin 1 beta (IL-1 ; QT00181657), Interleukin 4 (IL-4; QT01590316), Kelch-like ECHassociated protein 1 (Keap1; QT00189595), matrix metalloproteinase-2 (MMP2; QT00996254), matrix metalloproteinase-9 (MMP9; QT00178290), NADPH oxidase 2 catalytic subunit (Gp91 phox ; QT00195300), nuclear factor (erythroid 2)-like 2 (Nrf2; QT00183617), NADPH oxidase 2 intracellular regulatory subunit (p47phox; QT00189728), superoxide dismutase 1 (SOD1; QT00174888), superoxide dismutase 2 (SOD2; QT00185444), Tissue metallopeptidase inhibitor 1 (TIMP-1; QT00185304), Tumor necrosis factor (TNF; QT02488178), Thrombospondin 1 (TSP-1; QT01300607), and 
Measurement of ROS
Dihydroethidium (DHE; Invitrogen, Carlsbad, CA, USA; D1168) assays were performed on unfixed aortic rings and tPVAT sections to evaluate ROS production. Aortic rings were placed in a 96-well plate containing 
Nitric oxide bioavailability
Aortic NO production was measured according to the manufacturer's instructions by 4-amino-5-methylamino-2 ′ ,7 ′ -difluorofluorescein- 
Perivascular adipose tissue function
Thoracic PVAT homogenates were run according to the manufacturer's 
Aortic reactivity
Thoracic aortic rings (3 mm thick, cleaned of surrounding tissue; n = 14-16) were rinsed in physiological salt solution and mounted in a myobath chamber between a fixed point and a force transducer (World Precision Instruments, Sarasota, FL, USA) and prestretched to equilibrate for 1 h in Krebs-Henseleit buffer aerated with 95% O 2 and 5% CO 2 at 37 • C. After equilibration, aortic baseline tension was adjusted to 1 g. Vessel viability was checked with 50 mM KCl, and rings not generating a rapid response were excluded from the study.
To test EDD, aortic rings were preconstricted with phenylephrine (PE;
1 × 10 −7 M; Sigma-Aldrich; P6126) and a stable tension was reached and recorded, followed by increasing doses of MCh (from 1 × 10 −9 to 1 × 10 −5 M). Relaxation was calculated as the percentage relaxation for each dose of MCh from the following equation:
where z is the tension after PE 1 × 10 −7 M, x is the tension after a given dose of MCh, and y is the baseline tension.
After the relaxation curve, the system was washed again and allowed to return to baseline. To test the effect of tPVAT on EDD, tPVAT exudate or exudate generated after treatment with TNF -AB and/or NOX2ds-TAT was either snap frozen and used in crossover experiments or used immediately. Exudate was added to the bath, and rings were incubated for 30 min. Additionally, a subset of rings was incubated with the NO inhibitor L-NAME and underwent relaxation experiments both with and without the presence of tPVAT.
Pilot studies showed no difference in EDD between exudate and tPVAT tissue incubation. After the incubation, relaxation curves were carried out as described above. Aortas were treated with both NOX2ds-TAT and TNF-AB to assess the direct impact of these drugs on the aorta.
Finally, aortic rings both with and without tPVAT incubation were preconstricted with 1 × 10 −7 M PE and treated with increasing doses of sodium nitroprusside (SNP; from 1 × 10 −9 to 1 × 10 −5 M; MP Biomedical; 152061). preconditioned by a 20 mN 1 min stretch, after which all tension was removed (i.e. force = 0 mN). Rings were then stretched to 10 mN of force for 3 min, and the internal diameter and wall thickness were measured. Subsequently, the automated force transducer increased the aortic ring diameter by 25% of initial internal diameter every 3 min until mechanical failure. Stress and strain equations were modified from those used previously (Brooks et al., 2015) to match those used in large arteries (Fleenor et al., 2014) , and the slope of the stress-strain curve was used to determine the elastic modulus. Stress and strain were calculated as follows:
Aortic stiffness via elastic modulus
where Δd is the change in diameter, d(i) is initial diameter, L is the onedimensional load applied, H is wall thickness and D the length of the vessel.
Perivascular adipose tissue culture studies
To determine the direct impact of PVAT on mechanical stiffness, LZR aortic rings (n = 4 rings per treatment) were cultured for 72 h in RMPI + GlutaMAX + 25 mM Hepes (gibco R by Life Techonologies, Carlsbad, CA, USA) with streptomycin and kept in a CO 2 cell incubator at 37 • C in air supplemented with 5% CO 2 in the following conditions:
control (medium alone); LZR PVAT; OZR PVAT; or OZR PVAT + TNF -AB (4 M). For these experiments, four aortic ring segments were taken from an LZR and placed in separate wells of a six-well culture dish with 5 ml of medium, and three wells received 200 mg of tPVAT from one of the conditions listed above. Medium was discarded and replenished daily. After the 72 h of culture, aortic rings were subjected to the protocol described above to generate an elastic modulus.
Statistics
All data are represented as means ± SD. All experiments were run in duplicate and the results averaged for each animal. Data analysis and graph plotting were conducted using GraphPad Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA), and P < 0.05 was set as the mark for statistical significance. Comparisons between LZR and OZR were conducted using Student's unpaired t test. Repeated-measures ANOVA was used for treatment effects, the effect of tPVAT, and aortic ring relaxation, with Tukey's post hoc test for multiple comparisons. 
RESULTS
Animal characteristics
As expected, OZR presented with increased weight (P < 0.05; OZR 604 ± 28 g versus LZR 419 ± 40 g), mean arterial blood pressure (P < 0.05; OZR 135 ± 15 mmHg versus LZR 106 ± 4 mmHg), blood glucose (P < 0.05; OZR 184 ± 30 mg dl −1 versus LZR 98 ± 16 mg dl −1 ) and triglycerides (P < 0.05; OZR 124 ± 20 mg dl −1 versus LZR 25 ± 9 mg dl −1 ).
Thoracic PVAT-mediated aortic ROS production
Production of ROS was higher in OZR compared with LZR aorta (P < 0.05; Figure 1a ). We then incubated the LZR aorta with LZR tPVAT and identified a slight, non-significant reduction in ROS production.
In contrast, when the OZR aorta was incubated with OZR tPVAT, aortic ROS production was increased by ∼120% (P < 0.001; Figure 1a) .
Furthermore, the activation of aortic ROS production was significantly 
F I G U R E 1 Role of obese Zucker rat (OZR) thoracic perivascular adipose tissue (tPVAT) in activating production of aortic reactive oxygen species (ROS) and reducing nitric oxide. (a) Effect of tPVAT on on aortic (Ao) ROS production, with specific and non-specific inhibition of NADPH oxidases, [n = 8, lean Zucker rat (LZR) versus OZR compared by Student's unpaired t test and within-group effect assessed by repeated-measures ANOVA] was determined by incubating LZR aortas with LZR tPVAT and OZR aortas with OZR tPVAT. (b) Relative total superoxide dismutase (SOD) activity of aortic homogenates (n = 4, assessed by Student's unpaired t test). (c) Effect of tPVAT (LZR Ao with LZR tPVAT and OZR Ao with OZR tPVAT) on aortic endothelium-dependent dilatation (EDD; n = 16, assessed by repeated-measures ANOVA) and (d) maximal relaxation in the presence of the NO inhibitor L-NAME (n = 4-8, Ao versus Ao-tPVAT assessed by Student's paired t test). (e-g) To assess the role of tPVAT on aortic function, crossover experiments (LZR Ao with OZR tPVAT and OZR Ao with LZR tPVAT) were conducted to determine the effect of tPVAT on aortic ROS, NO and EDD (n = 8, assessed by repeated-measures ANOVA, LZR Ao versus OZR Ao assessed by Student's unpaired t test). Data are expressed as means ± SD. *Significant difference (P < 0.05) between LZR and OZR; # significant difference between tPVAT and Ao within group; and^significant difference of drug treatment compared with respective tPVAT. Abbreviations: MCh, Methacholine; Pe, Phenylephrine; PYRO, pyrogallol; RFU, relative fluorescence units inhibited when the OZR aorta was treated with apocynin, and to a lesser extent with NOX2ds-TAT ( Figure 1a ). The SOD activity in the OZR aorta was diminished compared with LZR (P < 0.001; Figure 1b ). The increased ROS production has the potential to impact NO production and EDD.
Effect of tPVAT on NO and aortic relaxation
The aortic EDD (without the presence of tPVAT) in OZR was blunted by ∼15% in comparison to LZR EDD (P < 0.01; Figure 1c ). In the OZR, tPVAT further blunted aortic EDD by ∼10% (P < 0.01) compared with OZR without tPVAT (Figure 1c ). In contrast, LZR aortic EDD in the presence of LZR tPVAT improved EDD by 5% (P < 0.05; Figure 1c ).
Treatment of the aorta with L-NAME removed the effects of both LZR and OZR tPVAT (Figure 1d ). Importantly, endothelium-independent dilatation in response to SNP was not different between the two groups in the presence or absence of tPVAT (P > 0.05; maximal relaxation: LZR Ao 101 ± 2%, LZR tPVAT-Ao 100 ± 5%, OZR Ao 98 ± 6% and OZR tPVAT-Ao 97 ± 14%). As expected, we found reduced NO bioavailability in the aorta from OZR compared with LZR ( Figure 1f ). Adding to this known finding, we showed that aortic NO production was further reduced by ∼20% (P < 0.01) in the presence of OZR tPVAT (Figure 1f ). In contrast, LZR tPVAT increased (P < 0.05) aortic NO production in the LZR by ∼15% (Figure 1f ). These data illustrate that tPVAT caused further impairment in OZR aortic EDD.
We then wanted to determine whether this was attributable to the release of cytokines from tPVAT or, in part, attributable to intrinsic properties of the OZR aorta. To assess this, we preformed crossover experiments, in which the LZR aorta was exposed to OZR tPVAT medium and vice versa.
Perivascular adipose tissue crossover treatments
Initially, we explored the effect of crossover tPVAT treatment on aortic ROS production. Interestingly, the LZR 'healthy' aorta was not protected against OZR tPVAT activation of aortic ROS production (P < 0.001; Figure 1e ). Additionally, LZR tPVAT was treated with pyrogallol to produce ROS. The LZR tPVAT with pyrogallol increased ROS production ( Figure 1e ) and decreased EDD from the LZR aorta (P < 0.05; maximal relaxation: LZR tPVAT + pyrogallol-Ao 74 ± 7%
versus LZR tPVAT-Ao 87 ± 4.2%) but not to the same extent as OZR tPVAT (P < 0.05; maximal relaxation: LZR tPVAT + pyrogallol-Ao 74 ± 7% versus OZR tPVAT-LZR Ao 64 ± 5%). We then incubated LZR tPVAT with the OZR aorta, which reduced aortic ROS production (P < 0.01; Figure 1e ). In contrast, when OZR tPVAT was incubated with the LZR aorta, NO production was reduced, with subsequently impaired aortic EDD (P < 0.01) in the LZR (Figure 1f,g ). Conversely, the crossover treatment improved (P < 0.01) NO production and aortic EDD in OZR treated with LZR tPVAT (Figure 1f,g ).
Thoracic PVAT environment
Gene expression
To assess the effect of MetS on the tPVAT environment, we initially compared the gene expression of key transcripts involved in adipose phenotype, pro-and anti-inflammatory cytokines and pro-and antioxidants. The OZR showed a significant reduction in uncoupling protein-1 (UCP-1) expression, suggesting a shift towards a 'whiter' phenotype (P < 0.01; Figure 2a ) and an increase in the immune cell markers CD68 (macrophages; P < 0.05) and CD8a (cytotoxic T cells; P < 0.05; Figure 2a ). This was accompanied by an increased expression of pro-inflammatory/pro-oxidative genes (Figure 2b ). We also identified a reduction in gene expression of the protective antiinflammatory/antioxidant genes, which could exacerbate the proinflammatory/pro-oxidative changes of tPVAT from OZRs (Figure 2c ).
With the observed increase in oxidative gene expression, we sought to measure ROS production and SOD activity in tPVAT.
Function of tPVAT
Reactive oxygen species were significantly increased in OZR tPVAT compared with LZR tPVAT (P < 0.001; Figure 3a) , attributable, in part, to a reduced SOD activity in OZR tPVAT (P < 0.001; Figure 3b ).
With the sizeable increase in ROS production, we were interested in the clearance of damaged cellular components. We found that proteasome activity was globally diminished in OZR tPVAT. This was shown by reduced (P < 0.01) V max across all three assays: LLVY, RLR and nLDnLP (chymotrypsin-like, trypsin-like and peptidylglutamyl-peptide hydrolysing active sites; Figure 3c ). This proteasome dysfunction was Data are expressed as means ± SD, *Significant difference in OZR versus LZR, minimum of twofold change and Student's unpaired t test P < 0.05, n = 3. Abbreviations: AdipoQ, adiponectin; CAT, catalase; CCL5, Chemokine (C-C motif) ligand 5; CCR, C-C motif chemokine receptor; CD, cluster of differentiation; GSR, glutathione reductase; IFN-, interferon gamma; IL, interleukin; Keap1, kelch-like ECH associated protein 1, NOX2, NADPH oxidase 2 catalytic subunit (GP91); p47phox, NADPH oxidase 2 intracellular regulatory subunit; NFR2, nuclear factor (erythroid 2)-like 2; SOD, superoxide dismutase; TNF, tumor necrosis factor; TSP-1, thrombospondin 1; and UCP-1, uncoupling protein-1 also highlighted by an increased expression of ubiquitin, suggesting a reduced ability to clear ubiquitinated proteins (Figure 3d ), which is linked to increased inflammation.
Proteasome dysfunction and build-up of ubiquitinated proteins are linked to increases in inflammation, thus we evaluated tPVAT cytokine production. Initially, we looked at chemoattractant cytokines because of the increased immune-specific gene expression.
Cytokine assays showed an increase (P < 0.05) in both monocyte chemoattractant protein-1 (MCP-1) and chemokine (C-X-C motif)
ligand-1 (KC/Gro; Figure 4a ). Furthermore, all cytokines profiled After observing a ∼10-fold increase in TNF gene expression and ∼10-fold increase in TNF secretion in OZR tPVAT, we repeated aortic function experiments with a TNF -AB to determine its role in orchestrating the observed dysfunction. Additionally, we targeted NOX2, the prominent NOX enzyme of inflammatory immune cells, because it is a known target of TNF .
Perivascular adipose tissue with TNF neutralization 3.6.1 Gene expression
We first sought to determine the role of TNF on OZR tPVAT gene expression. TNF -AB treatment (ex vivo) significantly downregulated phosphorylation of nuclear factor kappa-light-chain-enhancer (NF-B; 
Reactive oxygen species
Treatment with TNF -AB caused a marked reduction (P < 0.001) in the DHE signal from OZR tPVAT to levels similar to those observed with inhibition by NOX2ds-TAT (Figure 5c ). In turn, the TNF -AB treatment in OZR tPVAT completely inhibited the tPVAT activation of ROS in both OZR and LZR aorta (P < 0.001; Figure 5c ). Furthermore, highlighting the importance of TNF activation of NOX2 in OZR tPVAT dysfunction, inhibition with NOX2ds-TAT completely inhibited the tPVAT activation of ROS produced by the aorta (P < 0.001; Figure 5c ). To determine whether the diminished proteasome activity in OZR tPVAT was acutely mediated by TNF , we cultured OZR tPVAT with TNF -AB and ran all three proteasome assays. The results showed no effect of TNF -AB (V max : LLYV 1.2 ± 0.05, RLR 2.5 ± 0.07 and nLPnLD 0.5 ± 0.04; P > 0.05).
Nitric oxide and aortic reactivity
With TNF -AB treatment yielding beneficial effects on gene expression and ROS production, we examined its actions on NO and aortic EDD. Treatment with TNF -AB in OZR tPVAT inhibited the tPVAT-mediated reduction of NO production from OZR and LZR aortas (P < 0.001; Figure 5d ). In turn, TNF -AB treatment in OZR tPVAT completely inhibited tPVAT-mediated dysfunction of aortic EDD in both OZR and LZR (P < 0.01; Figure 5e ,f). To highlight the importance of NOX2 in the TNF -mediated aortic dysfunction, we treated OZR tPVAT with NOX2ds-TAT and demonstrated that aortic EDD was completely restored (P < 0.001; Figure 5e) ; however, the combination of TNF -AB and NOX2ds-TAT caused no further improvement (P > 0.05; maximal relaxation: 71 ± 3%). Additionally, the treatment of the aorta (without tPVAT) with TNF -AB and NOX2ds-TAT had no effects (maximal relaxation: OZR Ao 68 ± 2%, OZR Ao + TNF -AB 69 ± 3% and OZR Ao + NOX2ds-TAT 67 ± 2%).
To show the importance of tPVAT activation of aortic ROS production, the LZR and OZR aortas were pretreated with TEMPOL, which prevented the impaired EDD (P < 0.05; maximal relaxation: OZR tPVAT-Ao + TEMPOL 78 ± 2% versus OZR tPVAT-Ao 58 ± 2% versus OZR Ao 68 ± 2%). Our data to this point have established the role of OZR tPVAT in mediating NO regulation of smooth muscle tone, and thus functional aortic stiffness. Additionally, we assessed the role of MetS tPVAT on aortic remodelling and structural stiffness.
Elastic modulus
Aortic stiffness was increased (P < 0.01) by ∼90% in the OZR compared with LZR ( Figure 6a) ; therefore, we wanted to examine the role of tPVAT in OZR aortic stiffness. We first examined tPVAT gene The effect of ex vivo TNF -AB treatment on OZR tPVAT-mediated NO production (d) and EDD in OZR aorta (e) and the crossover experiment in LZR aorta (f; n = 5-8). Data are expressed as means ± SD.^Significant (P < 0.05) effect of treatment compared with control conditions assessed by repeated-measures ANOVA. Abbreviations: AdipoQ, adiponectin; IFN-, interferon gamma; IL, interleukin; MCh, methacholine; MMP, matrix metalloproteinase; NOX2, NADPH oxidase 2 catalytic subunit (GP91); Pe, phenylephrine; p47phox, NADPH oxidase 2 intracellular regulatory subunit; NFR2, nuclear factor (erythroid 2)-like 2; TIMP, tissue inhibitor of metalloproteinase; TNF, tumor necrosis factor; TSP-1, thrombospondin 1 expression and found an increase in MMP9 expression (P < 0.05) but no change in MMP2 and TIMP-1 (Figure 6b ). We then examined the aortic protein levels of TIMP-1, which were decreased in OZR compared with the LZR (Figure 6c ). Furthermore, activity levels of MMP9, assessed in tPVAT exudate, were increased in OZR compared with LZR, and treatment of tPVAT with the TNF -AB prevented the increase in MMP9 activity (Figure 6d ). This laid the groundwork for the potential role of OZR tPVAT to affect aortic remodelling. Next, we examined the direct contribution of tPVAT to aortic stiffness, and the role of TNF . Co-culture of the LZR aorta with LZR tPVAT did not alter the elastic modulus compared with culture control; however, the LZR aorta cultured with OZR tPVAT showed an increase (P < 0.01) in the elastic modulus (Figure 6e ), which was completely inhibited when the LZR aorta with OZR tPVAT were cultured with the TNF -AB (P < 0.01; Figure 6e ). 
DISCUSSION
Metabolic syndrome PVAT environment
Similar to what has been shown in obesity (Shimizu et al., 2014) , our data suggest a phenotypic 'whitening' of the MetS tPVAT, supported by the change in UCP-1 expression. Loss of UCP-1 and a white-like phenotype are associated with ROS (Lin et al., 2005) and inflammation (Sakamoto et al., 2013) . In the present study, the potential phenotypic shift in tPVAT was associated with increased KC/Gro and MCP-1 levels, resulting in increased inflammatory immune cell markers (CD68 and CD8a), which produce TNF and possess NOX2. Our data from inhibition of the NOX p47phox subunit suggest that NOX2 was largely responsible for the tPVAT ROS production. Furthermore, an increase in NOX2 activity coupled with a substantial reduction in SOD activity in OZR tPVAT is likely to account for the increased ROS production in tPVAT. Importantly, our data showed that TNF was a key mediator for the elevated ROS in MetS tPVAT. Activation of NOX2 ROS appears to be dependent on TNF , because the simultaneous treatment with both NOX2ds-TAT and TNF -AB did not cause a further reduction in ROS production. This is in line with the literature suggesting that multiple TNF functions are carried out by the activation of NADPH oxidases (Kim et al., 2007; Li, Fan, Christie, & Shah, 2005) . Additionally, the TNF -AB treatment showed partial restoration of tPVAT gene expression, probably owing to a direct action on TNF and subsequent reductions in ROS (Sen & Packer, 1996) resulting in the observed decrease in NF-B activation. This suggests that chronic changes in oxidative and inflammatory machinery might also be driven by TNF and its activation of NOX2. Interestingly, the inhibition of NOX and/or the use of the TNF -AB did not completely inhibit ROS production, and ROS levels were still well above those measured in LZR tPVAT. This highlights the role of other oxidative enzymes, and potentially other cytokine mediators, playing some role in tPVAT ROS production.
Recently, both obese human and mouse visceral adipose tissue was found to show reduced chymotrypsin-like activity in the proteasome and was linked to development of insulin resistance, a hallmark of MetS (Díaz-Ruiz et al., 2015) . We wanted to build upon these observations, as tPVAT is more protein dense than visceral adipose tissue, which we speculated would magnify the importance of proteasome function.
Reactive oxygen species are known to damage and misfold proteins, which are cleared by the 26S proteasome. The 26S proteasome is composed of the 20S core bound to one or two 19S regulatory particles, which feed ubiquitinated and damaged proteins into the 20S core (Smith, Fraga, Reis, Kafri, & Goldberg, 2011) . Our results showed increased ROS and, for the first time in tPVAT, impaired proteasome function. The accumulation of ubiquitinated proteins was probably attributable to the loss of proteasome capacity, and therefore, the accumulation of proteasomal substrates. Interestingly, diminished proteasome function was not attributable to the reduction of 20S proteasome levels (Figure 2) . The increased accumulation of damaged and misfolded proteins can lead to cellular and oxidative stress (Ghosh et al., 2015; Höhn, König, & Jung, 2016; Otoda et al., 2013) . Specifically, build-up of oxidized and ubiquitin proteins through activation of endoplasmic reticulum stress induced production of inflammatory cytokines (Ghosh et al., 2015) , suggesting that proteasome dysfunction might contribute to increased pro-inflammatory cytokine production.
Future endeavours will be aimed at assessing the causative and/or exacerbating role of the entire ubiquitin-proteasome system in disease-mediated PVAT dysfunction.
Regulation of aortic function by tPVAT
Our data showed a blunted aortic EDD in OZR, which was reduced further in the presence of OZR tPVAT. The impaired EDD was derived from reduced bioavailability of NO in OZR aorta, which was further reduced (∼20%) in the presence of OZR tPVAT. Pro-inflammatory cytokines and ROS, which were increased in OZR tPVAT, have the potential to interfere with NO bioavailability (Laursen et al., 2001; Yang & Rizzo, 2007) . The acute tPVAT impairment of the aorta was attributable to OZR tPVAT-derived TNF inducing aortic ROS. This is supported by TNF -AB inhibiting OZR tPVAT impairment of both OZR and LZR aortic EDD and the lack of effect of TNF -AB on OZR aorta without tPVAT EDD. The activation of ROS production (via NOX) can interfere with NO bioavailability (Vásquez-Vivar et al., 1998; Yang & Rizzo, 2007) . Our data implicate NOX, but not NOX2, in aortic ROS production, because NOX2ds-TAT had no effect on OZR aorta without tPVAT. This is in opposition to Serpillon et al. (2009) , who showed that p47phox inhibition in the aorta caused a profound reduction of ROS. We speculate that this difference might be attributable to the advanced diabetic state of the rats in the study by Serpillon et al. (2009) resulting in a shift in oxidative enzymes upon the development of type 2 diabetes, and the influence of advanced glycation end-product receptor signalling (Zhang et al., 2006) . Our data showed that NOX2 inhibition in OZR tPVAT had the same impact as TNF neutralization, suggesting that tPVAT impairment of the aorta is dependent on ROS.
We therefore created an oxidative environment experimentally with pyrogallol in healthy tPVAT, but this was unable to recreate the same level of aortic dysfunction as MetS tPVAT. This would suggest that the phenotypic changes in MetS tPVAT are essential for the production capacity of inflammatory mediators that activate aortic ROS and interfere with NO bioavailability.
Previous data have shown that TNF activates the production of ROS from oxidative enzymes, such as NADPH oxidase (Kim et al., 2007; Li et al., 2005) . In the present study, we showed that the activation of aortic ROS production by OZR tPVAT could be completely abolished by a TNF -AB. Likewise, albeit in a completely different vascular bed, the small resistance vessels from obese patients showed an increased gene expression of TNF in PVAT, and use of a TNF receptor inhibitor reduced vessel ROS production (Virdis et al., 2015) , but owing to the experimental design these authors were unable to differentiate between basal and PVAT activation of ROS.
In addition to direct activation of ROS, TNF mediates expression of IL-1 (Turner et al., 2007) , another stimulator of oxidative enzymes (Gurjar, Deleon, Sharma, & Bhalla, 2001 ). Additionally, IL-1 can act to enhance TNF signalling through regulation of TNF receptors (Saperstein, Chen, Oakes, Pryhuber, & Finkelstein, 2009 ).
This implicates IL-1 in a supportive role to TNF in mediating might play a role in chronic vascular dysfunction, as previously shown (Mikolajczyk et al., 2016) .
In addition, MetS altered levels of cytokines with direct impact on NO production. TSP-1, a multifunctional homotrimeric matrix glycoprotein, was released from tPVAT at a higher concentration in OZR than LZR. Importantly, TSP-1 can inhibit endothelial nitric oxide synthase (eNOS) activation and thus reduce NO production (Isenberg, Martin-Manso, Maxhimer, & Roberts, 2009 ). Furthermore, TSP-1 has a direct role in mediating immune infiltration (Mandler, Nurkiewicz, Porter, & Olfert, 2017) , a key source of tissue inflammation. However, TSP-1 expression can also be mediated by TNF signalling (Fairaq, Goc, Artham, Sabbineni, & Somanath, 2015) , suggesting a role for TNF mediating TSP-1 production as a potential mechanism of tPVATmediated aortic dysfunction in MetS. Another potential mechanism for the reduced NO bioavailability could be the reduced release of adiponectin from OZR tPVAT. Adiponectin can inhibit inflammation (Wang et al., 2014) and promote NO production (Wang & Scherer, 2008) . This is in concurrence with data showing that PVAT-derived adiponectin regulates small (100-150 m in diameter) peripheral artery function (Greenstein et al., 2009 ). The chronic loss or TNF inhibition of adiponectin stimulating (Wang & Scherer, 2008 ) eNOS gene expression might play a part in the pathological loss of vascular eNOS. The chronic effect of tPVAT-derived TNF on the aorta is beyond the scoop of the present study and warrants future investigations.
Thoracic PVAT-mediated aortic stiffness
In addition to NO regulation of EDD, previous studies have shown that NO is an essential regulator of ECM remodelling and aortic structure (Gurjar et al., 1999; Jenkins et al., 1998) . In obese and aged mice, tPVAT was shown to increase arterial stiffness through alterations of oxidative status, leading to elastin fragmentation (Chen et al., 2013; Fleenor et al., 2014) . However, PVAT might also affect ECM remodelling directly, because adipocytes and immune cells express
MMPs (Bouloumie, Sengenes, Portolan, Galitzky, & Lafontan, 2001; Chakraborti, Mandal, Das, Mandal, & Chakraborti, 2003) , in particular MMP9, which is highly associated with aortic stiffness and displays elastase activity (Yasmin et al., 2005) . The fragmentation of elastin increases aortic stiffness by causing the loading of collagen fibres at lower pressures (Lakatta & Levy, 2003) . Thoracic PVAT production of TNF might play an important role in the aortic stiffening with MetS through a number of pathways. First, TNF is known to stimulate the production of MMP9 (Wu, Sie, Kuan, & Lin, 2013) , and we found that OZR tPVAT had increased MMP9 activity, which was associated with increased stiffness. Inhibition of TNF by TNF -AB treatment decreased both MMP9 activity and aortic stiffness. Second, TNF can indirectly stimulate MMP9 though its promotion of other cytokines, whereby both IL-1 and TSP-1 can activate MMP9 (Brown, Jones, Laird, Hudson, & Long, 2007; Donnini, Morbidelli, Taraboletti, & Ziche, 2004) and active MMP9 can cleave TNF (Gearing et al., 1994) and IL-1 into active forms (Schönbeck, Mach, & Libby, 1998) .
Third, ROS has also been implicated in the fragmentation of elastin (Chen et al., 2013; Fleenor et al., 2014) , thus TNF activation of ROS may also play a role in the observed aortic stiffness in our study.
Fourth, reduced levels of TIMP-1 (a tissue inhibitor of MMPs) can also add to MMP9-mediated aortic dysfunction (Roderfeld et al., 2007) .
Further research into a causative effect of tPVAT derived MMPs is warranted.
Clinical outlook
The findings from the present study might help to elucidate mechanisms underlying increased aortic stiffness. Our data suggest that adding treatment for adipose tissue dysfunction to a multifaceted therapeutic approach in MetS might improve vascular function. Our data identify tPVAT-localized NOX2 as an essential component of tPVAT-mediated aortic dysfunction. As NOX2 is predominantly found in immune cells (Bedard & Krause, 2007) 
Limitations
A limitation of our co-culture experiment was the lack of intraluminal flow in the aortic rings, which is an important factor for shear stressmediated release of NO and regulation of stiffness. However, the use of a medium control helps to account for the increase in stiffness attributable to the lack of flow. Additionally, it was not possible to conduct crossover studies examining the effect of LZR tPVAT coculture on OZR aortic stiffness owing to the limited availability of LZR tPVAT. Finally, the experiments on aortic function were conducted ex vivo and might not reflect the magnitude of impairment imposed by tPVAT in vivo. However, many logistical hurdles remain in assessing tPVAT regulation of the aorta in vivo. We believe that our data clearly
show that OZR tPVAT can activate aortic ROS and impair aortic function, which warrants future investigations of OZR tPVAT cytokine concentrations in vivo.
Conclusions
In summary, we are the first to show in MetS a comprehensive picture of tPVAT TNF production, which regulates gene expression and ROS production (specifically NOX2-derived ROS) in the tPVAT. Additionally, we showed global reductions in proteasome function in MetS tPVAT.
These effects of MetS on tPVAT increase the production of TNF , TSP-1 and IL-1 and decrease production of IL-10 and adiponectin, which leads to a reduction in NO, EDD and MMP9 activity, and increases in structural stiffness. These data suggest that tPVAT dysfunction is a major driving force in aortic impairment in MetS and highlight the potential for adipocentric therapeutics.
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